rimeporide
Small moleculeexperimental
Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation. it has been granted orphan drug status by the European Medicines Agency. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02710591)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sodium/hydrogen exchangerINHIBITOR
NHE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N- Mol. weight
- 333.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRimeporide ↗
- ChEMBLCHEMBL2107802 ↗
Also known as
- rimeporide
- rimeporide
- rimeporide
- rimeporide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02710591 | Phase 1 | Mar 1, 2016 | EspeRare Foundation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EspeRare Foundation | Academic/Hospital | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1